Imran Eba

Action Potential Venture Capital is an evergreen strategic venture capital fund of GlaxoSmithKline which closed at $1 million in 213 and is managed by a small dedicated team based in Cambridge Massachusetts and Palo Alto California. The fund focuses on investments in companies developing pioneering bioelectronic medicines (essentially neuromodulation devices) and related enabling technologies. The initial investments are typically ranging from $5-$7 million in Series A and the fund will also consider follow-on investments. Action Potential Venture Capital looks for investment opportunities globally.
Website:
www.gsk.com
Sector Interest
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Action Potential Venture Capital
Partner 

Laura Eggink

Website:
www.susavion.com
Susavion Biosciences Inc.
President 

Mr Glenn Engelmann United States

McDermott Will & Emery is a premier international law firm with a unique focus in representing life sciences companies and investors in a wide variety of transactional, intellectual property and regulatory matters.  Through our Life Sciences Entrepreneurs Acceleration Program ("LEAP") we provide early stage medical device, pharmaceutical, biotechnology and diagnostic companies access to sophisticated legal services.  Learn more here: http://www.mwe.com/leap/

Website:
www.mwe.com
Service Provider Type
Medtech Phase of Development
Unique Capabilities
Life Sciences Entrepreneurs Acceleration Program (LEAP)

McDermott Will & Emery is dedicated to investing in innovation and serving the early stage life sciences community that creates new and revolutionary products and services. We understand that sophisticated legal services are necessary to help these groundbreaking individuals and organizations succeed. McDermott is proud to have created the Life Sciences Entrepreneurs Acceleration Program (LEAP) to help qualifying entrepreneurs and young companies avoid costly mistakes and chart their courses to success by providing support and affordable access to strategic legal advice. We provide these organizations with high quality legal services during the earliest stages of corporate life through engagement incentives in the form of deferred fees, discounts, fixed-fee arrangements and/or awards.

We understand that early stage life sciences clients need legal advice in such complex areas as corporate formation, financing, intellectual property, licensing and collaborations, and employee benefits. Our Life Sciences Industry Group has a deep bench of lawyers that are highly regarded in these specific practices. Our corporate lawyers have demonstrated success in advising life sciences companies on the full range of transactional legal needs, including licensing and partnering, mergers and acquisitions, venture capital, public offerings and royalty stream financing. Our intellectual property lawyers are renowned for protecting the IP rights of our clients both in and out of court. Finally, McDermott is a pioneer in the field of employee benefits and has been advising life sciences companies on various compensation strategies to both secure and maintain leadership.

McDermott Will & Emery
Vice Chair, Life Sciences McDermott Will & Emery 

Robin Engstrom

TriNet
Regional Sales Consultant, Life Sciences and Biotech 

Lesley Esford Canada

The National Research Council- Industrial Research Assistance Program (NRC-IRAP) is a Canadian federal government program that offers financial and advisory services to accelerate the growth of businesses through innovation and technology. Regarded worldwide as one of the most successful programs of its kind, NRC-IRAP is a vital component of Canada’s innovation system

 

National Research Council of Canada
Strategic Business Advisor